Riskpilot← Back to searchSign inGet full accessFABU Medical AB
ABActiveOrg 5566511670Fenjavägen 5General medical practice activities · NACE 8621Est. 20032 employees
Revenue 2024
SEK 4,6M
+14% vs 2023
EBITDA margin
52.9%
+24% vs 2023
Equity ratio
76.2%
Financial strength
Net profit 2024
SEK 1,9M
+27% vs 2023
| Revenue | SEK 4,6M | +14% |
| EBITDA | SEK 2,4M | +24% |
| Net profit | SEK 1,9M | +27% |
| Total assets | SEK 3,9M | +21% |
| Equity | SEK 3M | +17% |
| Employees | 2 | — |
Legal name
FABU Medical AB
Org number
5566511670
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
6 november 2003
Share capital
SEK 100 000
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva läkarpraktik, handel med och förvaltning av fast egendom och värdepapper samt utöva därmed förenlig verksamhet.
Address
Fenjavägen 5
Phone
+4687557950
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 103 | 3 514 | 3 878 | 4 008 | 4 550 |
| Staff expenses | — | — | −66 | −1 338 | −1 403 |
| EBITDA | 782 | 3 188 | 3 126 | 1 944 | 2 405 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 782 | 3 188 | 3 126 | 1 944 | 2 405 |
| Net financials | −2 | — | −187 | −129 | 30 |
| Profit before tax | 780 | 3 188 | 1 727 | 1 966 | 2 435 |
| Tax | −205 | −657 | −396 | −437 | −500 |
| Net profit | 575 | 2 531 | 1 331 | 1 529 | 1 935 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 578 | 5 027 | 5 371 | 3 218 | 3 883 |
| Equity | 2 133 | 2 664 | 3 995 | 2 525 | 2 959 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 183 | 2 101 | 584 | 53 | 283 |
| Total debt | 183 | 2 101 | 584 | 53 | 283 |
EBITDA margin
52.9%
This company
15.8%
Market median
+235% vs market
20202024
Equity ratio
76.2%
This company
38.2%
Market median
+99% vs market
20202024
Return on equity
65.4%
This company
18.4%
Market median
+255% vs market
20202024
Net profit margin
42.5%
This company
8.1%
Market median
+425% vs market
20202024
Asset turnover
1.17×
This company
1.12×
Market median
+4% vs market
20202024
Debt / equity
0.31×
This company
0.62×
Market median
+50% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MT Chief Auditor | Chief Auditor | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Undén Invest AB
FABU Medical AB Board members of FABU Medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Therese Janelind | Chief Auditor | 0 companies |
| Anne Birgitte Undén | Board of Directors | 0 companies |
| Ebba Josephine Undén | Deputy Board Member | 0 companies |